Kura Oncology logo
Kura Oncology
KURA | NASDAQ
Chart Builder DCF Calculator
$7.09
-$0.68 (-8.75%)
At close: Nov 16, 2026, 4:00 PM ET
$7.35
+$0.26 (+3.67%)
After-hours: Nov 16, 2026, 7:57 PM ET

Kura Oncology Company Profile

Company profile explained

Company Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Key Executives

Name Position
Troy Edward Wilson Chairman, Chief Executive Officer & President
Jennifer Fulk Chief Financial Officer
Kathleen Ford Chief Operating Officer
Teresa Brophy Bair Chief Legal Officer & Corporate Secretary
Brian T. Powl Chief Commercial Officer
Francis J. Burrows Chief Scientific Officer
Greg Mann Senior Vice President of Investor Relations & Corporate Affairs
Mollie Leoni Chief Medical Officer
Roger Bakale Senior Vice President of Manufacturing & Supply Chain
Samir Vattompadam Senior Vice President of Global Program Leadership
Thomas Doyle Senior Vice President of Finance & Accounting

Latest SEC Filings

Date Type Title
Oct 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Sep 29, 2026 4 Filing
Sep 29, 2026 4 Filing
Sep 29, 2026 4 Filing
Sep 29, 2026 4 Filing
Sep 29, 2026 4 Filing
Sep 25, 2026 4 Filing
Sep 10, 2026 4 Filing
Sep 10, 2026 3 Filing
Sep 09, 2026 8-K Current Report
View All SEC Filings ➞
Kura Oncology
Kura Oncology logo
Country United States
IPO Date Sep 16, 2015
Industry Biotechnology
Sector Healthcare
Employees 260
CEO Troy Wilson

Contact Details

4930 Directors Place San Diego, California 92121 United States

Stock Details

Ticker Symbol KURA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001422143
CUSIP Number 50127T109
ISIN Number US50127T1097
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.